The company reiterated its financial outlook for the year but is struggling to predict the likely impact of pharmaceutical ...

The World Federation of Hemophilia (WFH) and WFH USA, together with Sanofi, through its philanthropic organization Foundation ...

Sanofi reports Q1 growth with Altuviiio sales doubling to €251M and Dupixent reaching €3.5B; company terminates two cancer ...

As Sanofi anticipates sales of immunotherapy juggernaut Dupixent reaching a major $22 billion by the end of the decade, ...

Granite will focus on two antibody therapies, both targeting crucial players in the inflammatory cascade to address ...

The pharmaceutical company said the profit was driven by a higher gross margin and slower operating expense growth.

France's Sanofi reported first-quarter profit that beat analysts' expectations on Thursday, boosted by strong demand for its anti-inflammatory drug Dupixent, as well as newer treatments and vaccines.

In a report released on April 22, Nicolas Pauillac from Kepler Capital maintained a Hold rating on Sanofi (SNYNF – Research Report). The ...